The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
By 2030, How Much Growth In Market Size Is Expected For The Kovaltry Market?
Historical growth was driven by safety issues associated with plasma-derived factors, advancements in recombinant technology, an increase in hemophilia A diagnoses, the expansion of treatment centers, and enhanced patient survival rates.
During the forecast period, growth is expected to stem from the increasing adoption of prophylaxis therapy, the expansion of home infusion programs, enhanced access in emerging markets, ongoing innovation in recombinant factors, and stable demand for standard recombinant factor VIII (rFVIII) therapies. Key trends anticipated in this period include a pronounced shift toward recombinant factor VIII therapies, the expansion of prophylactic treatment for hemophilia A, a strong emphasis on developing infection-free clotting factor products, the growth of home-based hemophilia management strategies, and the implementation of personalized dosing regimens for bleeding disorders.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20133&type=smp
Which Significant Factors Are Encouraging Growth In The Kovaltry Market?
The kovaltry market is anticipated to be driven by the increasing incidence of hemophilia. Hemophilia is an inherited, uncommon bleeding condition characterized by inadequate blood clotting, resulting from a lack or insufficiency of clotting factors VIII and IX. This increase in hemophilia prevalence stems from elements like genetic mutations, enhanced awareness and diagnostic methods, and progress in medical technologies enabling more effective detection and reporting. Kovaltry plays a crucial role in managing hemophilia by ensuring sufficient and consistent clotting factor replacement, thereby reducing bleeding episodes. It supports ongoing patient care, enhancing quality of life and minimizing complications. For example, the Australian Bleeding Disorders Registry, an Australian government body, indicated in June 2024 that the total count of individuals with hereditary haemophilia in Australia reached 8,034 in 2024, an increase from 7,850 in 2022. Consequently, the rising prevalence of hemophilia propels the kovaltry market. The kovaltry market is expected to be propelled by an increase in the aging population. This demographic rise is a result of longer life expectancies, decreasing birth rates, and medical advancements that improve longevity. Kovaltry is relevant for older individuals with hemophilia A, as it helps manage bleeding incidents and avert complications, considering that seniors are at higher risk of bleeding due to age-related health and vascular changes. For instance, Age UK, a charity in the UK dedicated to older people, stated in July 2023 that England had 11 million individuals aged over 65 that year. This figure is predicted to increase by 10% in the next five years and by 32% by 2043, representing an additional 1.1 million and 3.5 million people, respectively. Therefore, the expanding aging population will fuel the kovaltry market.
How Are Different Segment Groups Identified Within The Kovaltry Market?
The kovaltry market covered in this report is segmented –
1) By Formulations: Injectable Formulation (Lyophilized Powder), Ready-To-Use Solutions
2) By Indications: Treatment Of Hemophilia A, Prophylaxis Of Hemophilia A, Management Of Bleeding Episodes
3) By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients
4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies
5) By End Users: Hospitals, Hemophilia Treatment Centers, Speciality Clinics, Home Healthcare Providers
Who Are The Key Market Participants In The Kovaltry Market?
Major companies operating in the kovaltry market are Bayer HealthCare LLC
Access The Complete Kovaltry Market Report:
https://www.thebusinessresearchcompany.com/report/kovaltry-global-market-report
Which Geographic Region Represents The Largest Kovaltry Market Share?
North America was the largest region in the kovaltry market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kovaltry market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model